143 related articles for article (PubMed ID: 31123687)
1. Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma.
Bommareddy PK; Lowe DB; Kaufman HL; Rabkin SD; Saha D
J Biol Methods; 2019; 6(2):. PubMed ID: 31123687
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemistry for Tumor-Infiltrating Immune Cells After Oncolytic Virotherapy.
Saha D; Rabkin SD
Methods Mol Biol; 2020; 2058():179-190. PubMed ID: 31486038
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.
Saha D; Martuza RL; Rabkin SD
Immunotherapy; 2018 Jul; 10(9):779-786. PubMed ID: 30008259
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.
Meisen WH; Wohleb ES; Jaime-Ramirez AC; Bolyard C; Yoo JY; Russell L; Hardcastle J; Dubin S; Muili K; Yu J; Caligiuri M; Godbout J; Kaur B
Clin Cancer Res; 2015 Jul; 21(14):3274-85. PubMed ID: 25829396
[TBL] [Abstract][Full Text] [Related]
5. Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.
Saha D; Martuza RL; Rabkin SD
Cancer Cell; 2017 Aug; 32(2):253-267.e5. PubMed ID: 28810147
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic effect of dual fluorescent-labeled oncolytic herpes simplex virus type 1 on mouse tumorigenic cell lines.
Abdoli S; Roohvand F; Teimoori-Toolabi L; Shayan S; Shokrgozar MA
Res Pharm Sci; 2019 Feb; 14(1):27-35. PubMed ID: 30936930
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of immunologic parameters in canine glioma patients treated with an oncolytic herpes virus.
Chambers MR; Foote JB; Bentley RT; Botta D; Crossman DK; Della Manna DL; Estevez-Ordonez D; Koehler JW; Langford CP; Miller MA; Markert JM; Olivier AK; Omar NB; Platt SR; Rissi DR; Shores A; Sorjonen DC; Yang ES; Yanke AB; Gillespie GY
J Transl Genet Genom; 2021; 5(4):423-442. PubMed ID: 35342877
[TBL] [Abstract][Full Text] [Related]
8. A novel in situ multiplex immunofluorescence panel for the assessment of tumor immunopathology and response to virotherapy in pediatric glioblastoma reveals a role for checkpoint protein inhibition.
Bernstock JD; Vicario N; Rong L; Valdes PA; Choi BD; Chen JA; DiToro D; Osorio DS; Kachurak K; Gessler F; Johnston JM; Atkinson TP; Whitley RJ; Bag AK; Gillespie GY; Markert JM; Maric D; Friedman GK
Oncoimmunology; 2019; 8(12):e1678921. PubMed ID: 31741780
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection.
Jarnagin WR; Zager JS; Klimstra D; Delman KA; Malhotra S; Ebright M; Little S; DeRubertis B; Stanziale SF; Hezel M; Federoff H; Fong Y
Cancer Gene Ther; 2003 Mar; 10(3):215-23. PubMed ID: 12637943
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic herpes simplex virus and immunotherapy.
Ma W; He H; Wang H
BMC Immunol; 2018 Dec; 19(1):40. PubMed ID: 30563466
[TBL] [Abstract][Full Text] [Related]
11. The Oncolytic herpes simplex virus type-1 (HSV-1) vaccine strain VC2 causes intratumor infiltration of functionally active T cells and inhibition of tumor metastasis and pro-tumor genes VEGF and PDL1 expression in the 4T1/Balb/c mouse model of stage four breast cancer.
Nabi R; Musarrat F; Menk P Lima JC; Langohr IM; Chouljenko VN; Kousoulas KG
Front Mol Biosci; 2023; 10():1199068. PubMed ID: 37388243
[No Abstract] [Full Text] [Related]
12. Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy.
Qiao J; Dey M; Chang AL; Kim JW; Miska J; Ling A; M Nettlebeck D; Han Y; Zhang L; Lesniak MS
Oncoimmunology; 2015 Aug; 4(8):e1022302. PubMed ID: 26405578
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo.
Yin L; Zhao C; Han J; Li Z; Zhen Y; Xiao R; Xu Z; Sun Y
Ther Clin Risk Manag; 2017; 13():117-130. PubMed ID: 28223815
[TBL] [Abstract][Full Text] [Related]
14. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
[TBL] [Abstract][Full Text] [Related]
15. TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response.
Han J; Chen X; Chu J; Xu B; Meisen WH; Chen L; Zhang L; Zhang J; He X; Wang QE; Chiocca EA; Kaur B; Caligiuri MA; Yu J
Cancer Res; 2015 Dec; 75(24):5273-82. PubMed ID: 26631269
[TBL] [Abstract][Full Text] [Related]
16. Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment.
Denton NL; Chen CY; Hutzen B; Currier MA; Scott T; Nartker B; Leddon JL; Wang PY; Srinivas R; Cassady KA; Goins WF; Cripe TP
Mol Ther Oncolytics; 2018 Dec; 11():62-74. PubMed ID: 30505937
[TBL] [Abstract][Full Text] [Related]
17. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
Varghese S; Rabkin SD; Liu R; Nielsen PG; Ipe T; Martuza RL
Cancer Gene Ther; 2006 Mar; 13(3):253-65. PubMed ID: 16179929
[TBL] [Abstract][Full Text] [Related]
18. Multi-color Flow Cytometry for Comprehensive Analysis of the Tumor Immune Infiltrate in a Murine Model of Breast Cancer.
Almeida AS; Fein MR; Egeblad M
Bio Protoc; 2021 Jun; 11(11):e4012. PubMed ID: 34250200
[TBL] [Abstract][Full Text] [Related]
19. Arming HSV-Based Oncolytic Viruses with the Ability to Redirect the Host's Innate Antiviral Immunity to Attack Tumor Cells.
Fu X; Tao L; Wu W; Zhang X
Mol Ther Oncolytics; 2020 Dec; 19():33-46. PubMed ID: 33024817
[TBL] [Abstract][Full Text] [Related]
20. Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model.
Alessandrini F; Menotti L; Avitabile E; Appolloni I; Ceresa D; Marubbi D; Campadelli-Fiume G; Malatesta P
Oncogene; 2019 Jun; 38(23):4467-4479. PubMed ID: 30755732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
